Glykon Granted Hydroxycitric Acid (HCA) Blood Pressure Patent

March 21, 2006 (Press Release) -- For_Immediate_Release:Las Vegas, NV, March 21, 2006 — The Unites States Patent and Trademark Office has granted to Glykon Technologies Group, LLC claims regarding the use of (–)-hydroxycitric acid, (–)-hydroxycitrate and HCA-related compounds for regulating blood pressure. Glykon now has six issued patents covering the use of HCA for insulin metabolism and blood sugar regulation (Syndrome X), regulation of glucocorticoids and leptin; bone mineralization and osteoporosis; wound healing and immune modulation. The company also has patented multiple technologies greatly expanding the range of available delivery forms for HCA as well as improving its assimilation and activity.Glykon’s patent claims are now being confirmed by outside research. A presentation at the 46th American College of Nutrition Annual Meeting examined blood pressure, insulin levels and inflammation with the oral intake of three forms of hydroxycitrate (HCA) at doses resembling those used by humans. (1) All HCA forms significantly lowered blood pressure and trended towards reduced CRP and TNF-alpha, the potassium-magnesium HCA significantly. Potassium and potassium-magnesium HCA dramatically improved insulin sensitivity, but the potassium-calcium HCA showed no benefit. The weaker showing of potassium-calcium HCA in most areas may be the result of limited assimilation due to the presence of calcium and also the presence of the undesirable HCA lactone. Dutch scientists have published similar results regarding potassium-calcium HCA. (2) Differences in the quality of HCA salts on the market may be responsible for the inconsistent findings of researchers. (3) Researchers at InterHealth Nutraceuticals have indicated that findings of toxicity with a particular hydroxycitric acid product tested in Japan were due to the high amount of HCA lactone found in the item produced for Nippon Shinyaku by Renaissance Herbs, Inc. (4) Liquid HCA and HCA salts delivered in acidic beverages are characterized by elevated lactone levels. Based in Las Vegas, Nevada, Glykon specializes in research, intellectual property development and licensing. On February 4, 2005, Glykon terminated its licensing agreement with Renaissance Herbs, Inc. covering uses and delivery systems for (–)-hydroxycitric acid and related products.
*(1) Clouatre D, Preuss H, et al. Hydroxycitrate at Physiologic Levels Influences Insulin Sensitivity, Blood Pressure and Inflammation in an Animal Model. (2) Louter-van de Haar J, et al. Comparison of the effects of three different (–)-hydroxycitric acid preparations on food intake in rats. Nutr Metab (Lond). 2005 Sep 13;2(1):23. (3) Wielinga PY, et al. Hydroxycitric acid delays intestinal glucose absorption in rats. Am J Physiol Gastrointest Liver Physiol. 2005 Jun;288(6):G1144-9. (4) Burdock G, et al. Garcinia cambogia toxicity is misleading. Food Chem Toxicol. 2005 Jun 30.

For more details contact: Southern California Liason Office:
Glykon Technologies Group, LLC
1223 Wilshire Blvd., #761
Santa Monica, CA 90403
Email: info@glykon.com

Visit Glykon Technologies Group, LLC on the web at http://www.glykon.com